Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03767621
Other study ID # iLITRO EPIC-07
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 19, 2019
Est. completion date November 30, 2025

Study information

Verified date February 2024
Source Fundación EPIC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The assessment of Left Main Coronary Artery (LMCA) lesions by means of coronary angiography renders serious limitations. Studies with a limited number of patients have shown that a value of FFR (Fractional Flow Reserve) above 0.80 identify a low risk of events in case of not performing revascularization in patients with intermediate stenosis in the LMCA. Although iFR (Instant wave Free Ratio) has recently been found equivalent to FFR The demonstration of the prognostic utility of iFR in patients with LMCA intermediate lesions could have an important clinical impact and justify its systematic use for the treatment decision in these high-risk patients.


Description:

The assessment of Left Main Coronary Artery (LMCA) lesions by means of coronary angiography renders serious limitations. In the case of intermediate stenoses (25-60%), invasive imaging tests, intravascular ultrasound (IVUS) or optical coherence tomography (OCT) or functional by determining the Fractional Flow Reserve (FFR), have been proposed to identify those patients who could benefit from revascularization. Studies with a limited number of patients have shown that a value of FFR above 0.80 identify a low risk of events in case of not performing revascularization in patients with intermediate stenosis in the LMCA. Although iFR (Instant wave Free Ratio) has recently been found equivalent to FFR in assessing the prognosis of patients with intermediate lesions, the validation of the prognostic power of this index in patients with intermediate LMCA lesions has not been demonstrated, although it is used in clinical practice assuming the results in other locations of the lesions. The demonstration of the prognostic utility of iFR in patients with LMCA intermediate lesions could have an important clinical impact and justify its systematic use for the treatment decision in these high-risk patients.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 300
Est. completion date November 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with intermediate lesion in the LMCA (25-60% angiographic stenosis) by visual estimation) in which the realization of a study with guide of pressure for the determination of the iFR. - Patients aged =18 years. - Patients able of giving informed consent. Exclusion Criteria: - Patients with indication for coronary surgery regardless of the significance of the LMCA lesion. - Patients with a LMCA lesion presenting with ulceration, dissection or thrombus. - Patients with previous arterial or venous graft lesion functioning in the territory irrigated by the LMCA (LMCA protected). - Patients with ACS (Acute Coronary Syndrome) with a potentially guilty lesion in the LMCA. - Patients unable to obtain informed consent. - Patients with known terminal illness that conditions a life expectancy less than 1 year. - Patients with hemodynamic instability with Killip III or IV class.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Indication of revascularization
Device: iFR/FFR

Locations

Country Name City State
Spain Hospital General Universitario de Albacete Albacete
Spain Hospital Universitario de Badajoz Badajoz
Spain Hospital Universitari Germans Trias I Pujol de Badalona Badalona
Spain Hospital Clinic I Provincial de Barcelona Barcelona
Spain Hospital de La Santa Creu I Sant Pau Barcelona
Spain Hospital Del Mar Barcelona
Spain Hospital Universitari Bellvitge Barcelona
Spain Hospital Universitari Vall D'Hebron Barcelona
Spain Hospital Universitario Puerto Real Cadiz
Spain Hospital General Universitario de Santa Lucia de Cartagena Cartagena Murcia
Spain Hospital General Universitario de Castellón Castellón De La Plana Valencia
Spain Hospital General de Ciudad Real Ciudad Real
Spain Hospital Universitario Reina Sofia Córdoba
Spain Hospital Clinico Universitario Virgen de La Arrixaca El Palmar Murcia
Spain Hospital Galdakao-Usansolo Galdakao Vizcaya
Spain Hospital Universitario de Cabueñes Gijón
Spain Hospital Universitari Doctor Josep Trueta Girona
Spain Hospital Universitario Virgen de Las Nieves Granada
Spain Hospital General Juan Ramón Jiménez Huelva
Spain Hospital de León León
Spain Hospital Universitari Lucus Agusti Lugo
Spain Clinica Universitaria de Navarra Madrid
Spain Hospital Clinico San Carlos Madrid
Spain Hospital de La Princesa Madrid
Spain Hospital Universitario de La Paz Madrid
Spain Hospital Universitario Virgen de La Victoria Málaga
Spain Hospital de Merida Mérida
Spain Hospital Universitario Central de Asturias Oviedo
Spain Hospital Universitario de Donostia San Sebastián
Spain Hospital Universitario Marqués de Valdecilla Santander
Spain Hospital Clinico Universitario de Santiago de Compostela Santiago De Compostela
Spain Hospital Universitari Joan Xxiii de Tarragona Tarragona
Spain Hospital Universitari Mutua de Terrassa Terrassa Barcelona
Spain Hospital Universitario Virgen de La Salud Toledo
Spain Hospital Clínico Universitario de Valencia Valencia
Spain Hospital Universitari I Politecnic La Fe Valencia
Spain Hospital Universitario Alvaro Cunqueiro Vigo
Spain Hospital Clinico Universitario Lozano Blesa Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Fundación EPIC

Country where clinical trial is conducted

Spain, 

References & Publications (10)

Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available. — View Citation

Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Harle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834. doi: 10.1056/NEJMoa1700445. Epub 2017 Mar 18. — View Citation

De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, Heyndrickx GR, Wijns W. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994 Mar;89(3):1013-22. doi: 10.1161/01.cir.89.3.1013. — View Citation

de la Torre Hernandez JM, Baz Alonso JA, Gomez Hospital JA, Alfonso Manterola F, Garcia Camarero T, Gimeno de Carlos F, Roura Ferrer G, Recalde AS, Martinez-Luengas IL, Gomez Lara J, Hernandez Hernandez F, Perez-Vizcayno MJ, Cequier Fillat A, Perez de Prado A, Gonzalez-Trevilla AA, Jimenez Navarro MF, Mauri Ferre J, Fernandez Diaz JA, Pinar Bermudez E, Zueco Gil J; IVUS-TRONCO-ICP Spanish study. Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries. JACC Cardiovasc Interv. 2014 Mar;7(3):244-54. doi: 10.1016/j.jcin.2013.09.014. — View Citation

de la Torre Hernandez JM, Hernandez Hernandez F, Alfonso F, Rumoroso JR, Lopez-Palop R, Sadaba M, Carrillo P, Rondan J, Lozano I, Ruiz Nodar JM, Baz JA, Fernandez Nofrerias E, Pajin F, Garcia Camarero T, Gutierrez H; LITRO Study Group (Spanish Working Group on Interventional Cardiology). Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. J Am Coll Cardiol. 2011 Jul 19;58(4):351-8. doi: 10.1016/j.jacc.2011.02.064. — View Citation

Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Ohagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Todt T, Venetsanos D, James SK, Karegren A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Frobert O; iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823. doi: 10.1056/NEJMoa1616540. Epub 2017 Mar 18. — View Citation

Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, Nelis O, Bartunek J, Vanderheyden M, Wyffels E, Barbato E, Heyndrickx GR, Wijns W, De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation. 2009 Oct 13;120(15):1505-12. doi: 10.1161/CIRCULATIONAHA.109.850073. Epub 2009 Sep 28. — View Citation

Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007 May 29;49(21):2105-11. doi: 10.1016/j.jacc.2007.01.087. Epub 2007 May 17. — View Citation

Sen S, Escaned J, Malik IS, Mikhail GW, Foale RA, Mila R, Tarkin J, Petraco R, Broyd C, Jabbour R, Sethi A, Baker CS, Bellamy M, Al-Bustami M, Hackett D, Khan M, Lefroy D, Parker KH, Hughes AD, Francis DP, Di Mario C, Mayet J, Davies JE. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol. 2012 Apr 10;59(15):1392-402. doi: 10.1016/j.jacc.2011.11.003. Epub 2011 Dec 7. — View Citation

Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment correlation between FFR>=0.80 and iFR >=0.89 Efficacy and correlation of two invasive indexes of functional assessment by intracoronary pressure guidance in intermediate lesions of the LMCA with a cut-off point to defer the treatment of FFR> = 0.80 (with intravenous adenosine) and iFR > = 0.89. the LMCA. 1 day
Primary Major Adverse Cardiac Events Composite of death, myocardial infarction, unplanned revascularisation 30 days
Primary Major Adverse Cardiac Events Composite of death, myocardial infarction, unplanned revascularisation 1 year
Primary Major Adverse Cardiac Events Composite of death, myocardial infarction, unplanned revascularisation 5 years
Secondary Assessment correlation between iFR and IVUS Assessment correlation between iFR and IVUS derived minimal luminal area 5 years
Secondary Death (all cause) Death (all cause) 30 days, 1 and 5 years
Secondary Death (cardiovascular) Death (cardiovascular) 30 days, 1 and 5 years
Secondary Non-fatal Myocardial Infarction Non-fatal Myocardial Infarction 30 days, 1 and 5 years
Secondary Non-fatal Myocardial Infarction related to the LMCA lesion Non-fatal Myocardial Infarction related to the LMCA lesion 30 days, 1 and 5 years
Secondary Revascularization Revascularization 30 days, 1 and 5 years
Secondary Revascularization of the target lesion Revascularization of the target lesion 30 days, 1 and 5 years
Secondary Myocardial Infarction related to target lesion revascularization Myocardial Infarction related to target lesion revascularization 30 days, 1 and 5 years
Secondary Stent Thrombosis in the target lesion revascularization Stent Thrombosis in the target lesion revascularization 30 days, 1 and 5 years
Secondary Restenosis of the stent in target lesion Restenosis of the stent in target lesion 30 days, 1 and 5 years
Secondary New revascularization of the target lesion New revascularization of the target lesion 30 days, 1 and 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A